Yener, Neslihan ParmakKılınçel, OğuzhanGündüz, Cem2023-11-032023-11-032018-05Gündüz, G. U. vd. (2018). ''How does usage of serotonin noradrenaline reuptake inhibitors affect intraocular pressure in depression patients?''. Journal of Ocular Pharmacology and Therapeutics, 34(4), 354-359.1080-76831557-7732https://doi.org/10.1089/jop.2017.0133https://www.liebertpub.com/doi/10.1089/jop.2017.0133http://hdl.handle.net/11452/34774Purpose: To evaluate anterior segment parameters and intraocular pressure (IOP) modifications in patients using serotonin noradrenaline reuptake inhibitors (SNRIs) due to major depressive disorder. Methods: This cross-sectional study included 170 eyes of 85 subjects. All subjects were divided into three groups: group 1 included 44 healthy control subjects, group 2 included 22 patients receiving antidepressants for 1 week to 6 months, and group 3 included 19 patients receiving antidepressants for >6 months. All subjects underwent a detailed ophthalmologic examination, including gonioscopy. Anterior segments of all subjects were evaluated with the Scheimpflug system and pupil diameter (PD), central corneal thickness, anterior chamber depth (ACD), anterior chamber volume, and anterior chamber angle (ACA) measurements were enrolled. Results: The median IOP was significantly lower in patients using antidepressants [16.0 (11.0-21.0) mmHg] than the control group [17.5 (12.0-21.0) mmHg] (P=0.041). The PD was significantly larger in patients using antidepressants [3.56 (2.29-5.60) mm] than the control group [2.95 (2.00-4.40) mm] (P=0.000). In the study group, PD was also significantly larger in patients using SNRIs for 6 months [3.67 (2.38-5.08) mm] than <6 months [3.31 (2.29-5.60) mm] (P=0.000). The median ACD was significantly lower in patients using antidepressants for 6 months [3.21 (2.52-4.06) mm] than the control group [3.44 (2.63-4.29) mm] (P=0.000). ACAs were measured between 25 degrees and 55 degrees by Scheimpflug imaging. Conclusions: Treatment of SNRIs causes mydriasis and decrease in width of ACD. These changes may not increase IOP as long as the patient has an open angle. SNRIs lead to decrease in IOP particularly in long-term usage.eninfo:eu-repo/semantics/closedAccessOphthalmologyPharmacology & pharmacyAnterior segment parametersIntraocular pressureSerotonin noradrenaline reuptake inhibitorsAngle-closure glaucomaVenlafaxineMechanismsExpressionPotentAgentsAdolescentAdultAntidepressive agentsCross-sectional studiesDepressive disorder, majorDuloxetine hydrochlorideFemaleHumansIntraocular pressureMaleMiddle agedSerotonin and noradrenaline reuptake inhibitorsVenlafaxine hydrochlorideYoung adultArticle0004251832000012-s2.0-8504690612935435934429446702OphthalmologyPharmacology & pharmacyBilateral; Angle Closure Glaucoma; TopiramateDuloxetineSerotonin noradrenalin reuptake inhibitorVenlafaxineAntidepressant agentDuloxetineSerotonin noradrenalin reuptake inhibitorVenlafaxineAdultAnterior chamber volumeAnterior eye chamber angleAnterior eye chamber depthArticleCentral corneal thicknessClinical evaluationControlled studyCross-sectional studyDrug effectFemaleGonioscopyHumanIntraocular pressureMajor clinical studyMajor depressionMaleOphthalmologyPsychopharmacotherapyPupilVisual system parametersAdolescentDrug effectsIntraocular pressureMajor depressionMiddle agedPathologyYoung adult